Aligos Therapeutics Stock (NASDAQ: ALGS) stock price, news, charts, stock research, profile.
Open | - |
Close | - |
Volume / Avg. | 0 / 393.330K |
Day Range | - - - |
52 Wk Range | 0.539 - 1.380 |
Market Cap | $55.662M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 35 |
Short Interest | 1.27% |
Days to Cover | 2.48 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Aligos Therapeutics (NASDAQ: ALGS) through any online brokerage.
Other companies in Aligos Therapeutics’s space includes: Kezar Life Sciences (NASDAQ:KZR), Gain Therapeutics (NASDAQ:GANX), Intensity Therapeutics (NASDAQ:INTS), Eagle Pharmaceuticals (NASDAQ:EGRX) and BioLine Rx (NASDAQ:BLRX).
The latest price target for Aligos Therapeutics (NASDAQ: ALGS) was reported by Piper Sandler on Tuesday, January 17, 2023. The analyst firm set a price target for 7.00 expecting ALGS to rise to within 12 months (a possible 851.60% upside). 0 analyst firms have reported ratings in the last year.
The stock price for Aligos Therapeutics (NASDAQ: ALGS) is $0.7356 last updated April 29, 2024 at 5:47 PM EDT.
There are no upcoming dividends for Aligos Therapeutics.
Aligos Therapeutics’s Q1 earnings are confirmed for Tuesday, May 14, 2024.
There is no upcoming split for Aligos Therapeutics.
Aligos Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.